株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全身性エリテマトーデス (SLE) ・ループス腎炎 (LN) - 世界の医薬品の予測と市場分析

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 296461
出版日 ページ情報 英文 407 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.95円で換算しております。
Back to Top
全身性エリテマトーデス (SLE) ・ループス腎炎 (LN) - 世界の医薬品の予測と市場分析 PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025
出版日: 2017年01月01日 ページ情報: 英文 407 Pages
概要

全身性エリテマトーデス (SLE) ・ループス腎炎 (LN) の治療薬市場は、2015年の12億米ドルから、2025年までに32億米ドルまで拡大すると見られています。市場は、2015年〜2025年のCAGR (複合年間成長率) で、10.6%の成長が予測されています。

当レポートでは、世界の全身性エリテマトーデス (SLE) ・ループス腎炎 (LN) 治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) など、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
  • 予測手法
  • SLE・LNの疫学予測
  • 議論

第5章 疾患の管理

  • 診断の概要
  • 治療の概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第6章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド、小分子
    • 抗マラリア性治療
    • ステロイド
    • メトトレキサート
    • ミコフェノール酸モフェチル
    • シクロホスファミド
    • アザチオプリン
    • カルシニューリン阻害薬
  • 製品プロファイル - 主要ブランド、生物製剤
    • ベンリスタ (belimumab)
    • リツキサン (rituximab)
  • マイナーな薬効分類

第7章 アンメットニーズ評価と機会分析

  • 概要
  • 優れた有効性と安全性を有する薬剤
  • 正確な臨床試験設計
  • 罹患率・死亡率の低下
  • 医師教育の改善
  • 精密で信頼性の高いバイオマーカー
  • 治療薬の順守率の向上

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 後期段階の開発中の有望薬
  • 初期段階の開発中の有望薬
  • その他の開発中の薬
  • バイオシミラー

第9章 現在・将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • GlaxoSmithKline
    • Roche
    • Bristol-Myers Squibb
    • AstraZeneca
    • Merck KGaA
    • Anthera Pharmaceuticals
    • Aurinia Pharmaceuticals
    • ImmuPharma
    • Pfizer

第10章 市場の見通し

  • 世界市場
  • 米国
  • EU5ヶ国
  • 日本

第11章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. The lupus market, which covers Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), is set to almost triple from $1.2 Billion in 2015 to $3.2 Billion by 2025, representing a compound annual growth rate of 10.6%. In addition, an increased prevalence of SLE and LN across the 7MM that, together with improved awareness of lupus, will result in a larger treated patient population.

As stated by Sebastian S. Gehrke, Healthcare Analyst, by 2025, the lupus treatment landscape is likely to be dominated by AstraZeneca's anifrolumab, a first-in-class anti-interferon monoclonal antibody (mAb), due to its efficacy in patients with cutaneous and articular involvement. Indeed, the Analyst projects the patient share targeted by anifrolumab to represent about 75% of all SLE patients, and the drug's success will drive the development and release of other anti-interferon mAbs beyond 2025.

Although this arrival of new pipeline drugs will satisfy the need for improved lupus medications, particularly for LN patients, a considerable share of patients will remain underserved with efficient medication. The mainstay of therapeutic options in lupus is delivered by off-label therapies that possess undesirable safety profiles, with modern drug discovery and development only resulting in the approval of Benlysta (belimumab) thus far, so unmet need is still considered to be high.

The report "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025" provides the overview of SLE and LN, including epidemiology, etiology, pathophysiology, as well current routine SLE and LN recommendations of all 7MM covered with comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. Moreover, it gives detailed analysis of the current and future market competition in the global SLE and LN marketplace and review of the key industry drivers, restraints and challenges.

Companies reviewed in this report: GlaxoSmithKline, Roche, Bristol-Myers Squibb, AstraZeneca (MedImmune), Merck KGaA, Anthera Pharmaceuticals, Aurinia Pharmaceuticals, ImmuPharma, Pfizer.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the SLE and LN marketplace.
  • What will be the effect of recent and upcoming biologics on the SLE and LN treatment landscape?
  • How will the upcoming first-in-class and me-too pipeline agents be received in the different markets?
  • What research and development (R&D) strategies will companies leverage to compete in the future SLE and LN marketplace?
  • Which patient population(s) are most likely to be targeted by newly introduced pipeline agents?

Key Findings

  • GlobalData has calculated that the global SLE and LN market generated about $1.2 billion in sales in 2015. This global market is expected to grow by an astonishingly strong compound annual growth rate (CAGR) of 10.6% from 2015-2025, reaching annual sales of $3.2 billion by the end of the forecast period. The majority of this growth will occur in the US, driven by an increased diagnosed disease prevalence of SLE and LN and the launch of three new first-in-class pipeline drugs (anifrolumab, Orencia [abatacept], and Lupuzor) and three improved therapeutic options (atacicept, blisibimod, and voclosporin). The SLE and LN market in the US is expected to grow at a CAGR of 10.4%, reaching sales of $2.8 billion by 2025. GlobalData estimates that sales in the 5EU to grow at a CAGR of 14.1% during the next 10 years, reaching $312.4m by 2025, while Japan will experience the lowest growth with a CAGR of 9.8%.
  • KOLs interviewed by GlobalData repeatedly identified the need for efficacious drugs as the most important clinical unmet need, with reducing lupus morbidity and mortality and the development of sensitive and reliable biomarkers for diagnosis and disease management as key areas of need as well.
  • GlobalData anticipates that opportunities will center on the development of safer and more efficacious drugs to treat the various disease manifestations in lupus.

Scope

  • Overview of SLE and LN, including epidemiology, etiology, pathophysiology, as well current routine SLE and LN recommendations of all 7MM covered.
  • Top-line SLE and LN market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the SLE and LN market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global SLE and LN marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global SLE and LN market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SLE and LN market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. SLE and LN Prevalence
    • 4.3.2. LN Classification
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for SLE and LN (2015-2025)
    • 4.5.1. Diagnosed Prevalent Cases of SLE
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of SLE
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of SLE
    • 4.5.4. Age-Standardized Diagnosed Prevalence of SLE
    • 4.5.5. Diagnosed Prevalent Cases of SLE Segmented by Severity
    • 4.5.6. Diagnosed Prevalent Cases of LN
    • 4.5.7. Diagnosed Prevalent Cases of LN Segmented by Class
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis Overview
    • 5.1.1. SLE Diagnosis
    • 5.1.2. LN Diagnosis
  • 5.2. Treatment Overview
    • 5.2.1. Treatment Guidelines and Leading Prescribed Drugs
  • 5.3. US
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. France
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Germany
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Italy
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. Spain
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. UK
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. Japan
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands, Small Molecules
    • 6.3.1. Antimalarials (numerous brand names)
    • 6.3.2. Steroids (numerous brand names)
    • 6.3.3. Methotrexate (numerous brand names)
    • 6.3.4. Mycophenolate Mofetil (numerous brand names)
    • 6.3.5. Cyclophosphamide (numerous brand names)
    • 6.3.6. Azathioprine (numerous brand names)
    • 6.3.7. Calcineurin Inhibitors (numerous brand names)
  • 6.4. Product Profiles - Major Brands, Biologics
    • 6.4.1. Benlysta (belimumab)
    • 6.4.2. Rituxan (rituximab)
  • 6.5. Minor Therapeutic Classes

7. Unmet Needs Assessment and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Drugs with Superior Efficacy and Safety Profiles, Particularly for LN
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Refined Clinical Trial Design Tailored to Heterogeneous Lupus Patient Populations
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Reduced Morbidity and Mortality in Lupus Patients
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Improved Physician Education
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Sensitive and Reliable Biomarkers for Diagnosis and Disease Management
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Increased Compliance Rates for SOC SLE and LN Therapies
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Therapy Type
  • 8.3. Promising Drugs in Late-Stage Clinical Development
    • 8.3.1. Blisibimod
    • 8.3.2. Atacicept
    • 8.3.3. Orencia (abatacept)
    • 8.3.4. Anifrolumab
    • 8.3.5. Lupuzor (IPP-201101, P-140)
    • 8.3.6. Voclosporin
  • 8.4. Promising Drugs in Early-Stage Clinical Development
    • 8.4.1. Overview
  • 8.5. Other Drugs in Clinical Development
  • 8.6. Biosimilars
    • 8.6.1. Overview
    • 8.6.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 8.6.3. Biosimilars in the Immunology Community
    • 8.6.4. By the Numbers: Biosimilars in Development for Potential Off-Label Use in SLE and LN
    • 8.6.5. The Impact of Biosimilars Will Be Felt Throughout the Pharmaceutical Industry
    • 8.6.6. Uptake of Biosimilars for SLE and LN Is Expected to Vary by Country/Region
    • 8.6.7. Biosimilars Forecast for SLE and LN

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. GlaxoSmithKline
    • 9.3.2. Roche
    • 9.3.3. Bristol-Myers Squibb
    • 9.3.4. AstraZeneca
    • 9.3.5. Merck KGaA
    • 9.3.6. Anthera Pharmaceuticals
    • 9.3.7. Aurinia Pharmaceuticals
    • 9.3.8. ImmuPharma
    • 9.3.9. Pfizer

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed SLE and LN Patients
    • 11.4.2. Drugs Included in Each Therapeutic Class
    • 11.4.3. Percent Drug-Treated Patients
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Directors
    • 11.7.3. Epidemiologists
    • 11.7.4. Global Director of Therapy Analysis and Epidemiology
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of SLE
  • Table 2: The 1982 Revised ACR Criteria For Classification of Systemic Lupus Erythematosus
  • Table 3: WHO and ISN/RPS Classification Systems for LN
  • Table 4: Risk Factors for SLE
  • Table 5: 7MM, Sources Used for Diagnosed Prevalence of SLE
  • Table 6: 7MM, Sources Used for Diagnosed Prevalence of Mild and Moderate/Severe SLE
  • Table 7: 7MM, Sources Used for Diagnosed Prevalence of LN
  • Table 8: 7MM, Sources Used for Diagnosed Prevalent Cases of LN Classified by the WHO Classification
  • Table 9: 7MM, Sources Used for Classifying LN by the ISN/RPS Classification
  • Table 10: 7MM, Sources Not Used in Epidemiological Analysis of SLE
  • Table 11: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, Select Years 2015-2025
  • Table 12: 7MM, Age-Specific Diagnosed Prevalent Cases of SLE, Both Sexes, N, Row (%), 2015
  • Table 13: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, Row (%), 2015
  • Table 14: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, Row (%), 2015
  • Table 15: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, Select Years 2015-2025
  • Table 16: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Classification, Row (%), 2015
  • Table 17: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Classification, Row (%), 2015
  • Table 18: Updated (1997) ACR Criteria for Classification of SLE
  • Table 19: The SLICC Clinical and Immunologic Criteria for Classification of SLE
  • Table 20: WHO and ISN/RPS Classifications of LN
  • Table 21: Treatment Guidelines for SLE and LN
  • Table 22: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2015
  • Table 23: Country Profile - US
  • Table 24: Country Profile - France
  • Table 25: Country Profile - Germany
  • Table 26: Country Profile - Italy
  • Table 27: Country Profile - Spain
  • Table 28: Country Profile - UK
  • Table 29: Country Profile - Japan
  • Table 30: Leading Treatments for SLE and LN, 2016
  • Table 31: Product Profile - Hydroxychloroquine
  • Table 32: Efficacy of Antimalarial Therapy in Lupus
  • Table 33: Safety of Antimalarial Therapy in Lupus
  • Table 34: Antimalarial Therapy SWOT Analysis, 2016
  • Table 35: Global Sales Forecasts ($m) of Antimalarials* for SLE and LN Therapy, 2015-2025
  • Table 36: Product Profile - Steroids
  • Table 37: Efficacy of Steroids in SLE Patients
  • Table 38: Safety of Long-Term Prednisone Use*
  • Table 39: Steroids SWOT Analysis, 2016
  • Table 40: Global Sales Forecasts ($m) of Steroids* for SLE and LN Therapy, 2015-2025
  • Table 41: Product Profile - Methotrexate
  • Table 42: Steroid-Sparing Effect of Methotrexate
  • Table 43: Safety of Methotrexate
  • Table 44: Methotrexate SWOT Analysis, 2016
  • Table 45: Global Sales Forecasts ($m) of Methotrexate* for SLE and LN Therapy, 2015-2025
  • Table 46: Product Profile - Mycophenolate Mofetil
  • Table 47: Efficacy of Mycophenolate Mofetil
  • Table 48: Safety of Mycophenolate Mofetil
  • Table 49: Mycophenolate Mofetil SWOT Analysis, 2016
  • Table 50: Global Sales Forecasts ($m) of Mycophenolate Mofetil for SLE and LN Therapy, 2015-2025
  • Table 51: Product Profile - Cyclophosphamide
  • Table 52: Efficacy of Cyclophosphamide
  • Table 53: Safety of Cyclophosphamide
  • Table 54: Cyclophosphamide SWOT Analysis, 2016
  • Table 55: Global Sales Forecasts ($m) of Cyclophosphamide* for SLE and LN Therapy, 2015-2025
  • Table 56: Product Profile - Azathioprine
  • Table 57: Efficacy of Azathioprine
  • Table 58: Safety of Azathioprine
  • Table 59: Azathioprine SWOT Analysis, 2016
  • Table 60: Global Sales Forecasts ($m) of Azathioprine* for SLE and LN Therapy, 2015-2025
  • Table 61: Product Profile - Calcineurin Inhibitors
  • Table 62: Efficacy of Calcineurin Inhibitors
  • Table 63: Safety of Calcineurin Inhibitors
  • Table 64: Calcineurin Inhibitors SWOT Analysis, 2016
  • Table 65: Global Sales Forecasts ($m) of Calcineurin Inhibitors* for SLE and LN Therapy, 2015-2025
  • Table 66: Product Profile - Benlysta
  • Table 67: Efficacy of Benlysta
  • Table 68: Safety of Benlysta
  • Table 69: Benlysta SWOT Analysis, 2016
  • Table 70: Global Sales Forecasts ($m) of Benlysta for SLE and LN Therapy, 2015-2025
  • Table 71: Product Profile - Rituxan
  • Table 72: Efficacy of Rituxan
  • Table 73: Safety of Rituxan
  • Table 74: Rituxan SWOT Analysis, 2016
  • Table 75: Global Sales Forecasts ($m) of Rituxan for SLE and LN Therapy, 2015-2025
  • Table 76: Summary of Minor Therapeutic Classes for the Treatment of SLE and LN, 2016
  • Table 77: Unmet Need and Opportunity in SLE and LN, 2016
  • Table 78: Key Late-Stage Pipeline Agents for SLE and LN, 2016
  • Table 79: Product Profile - Blisibimod
  • Table 80: Blisibimod SWOT Analysis, 2016
  • Table 81: Global Sales Forecasts (7MM) for Blisibimod in SLE and LN, 2015-2025
  • Table 82: Product Profile - Atacicept
  • Table 83: Atacicept SWOT Analysis, 2016
  • Table 84: Global Sales Forecasts ($m) for Atacicept in SLE and LN, 2015-2025
  • Table 85: Product Profile - Orencia
  • Table 86: Orencia SWOT Analysis, 2016
  • Table 87: Global Sales Forecasts ($m) for Orencia in SLE and LN, 2015-2025
  • Table 88: AstraZeneca's Anifrolumab - Key Phase II and Phase III Clinical Trials
  • Table 89: Product Profile - Anifrolumab
  • Table 90: Anifrolumab SWOT Analysis, 2016
  • Table 91: Global Sales Forecasts ($m) for Anifrolumab in SLE and LN, 2015-2025
  • Table 92: Product Profile - Lupuzor
  • Table 93: Lupuzor SWOT Analysis, 2016
  • Table 94: Global Sales Forecasts ($m) for Lupuzor in SLE and LN, 2015-2025
  • Table 95: Product Profile - Voclosporin
  • Table 96: Voclosporin SWOT Analysis, 2016
  • Table 97: Global Sales Forecasts ($m) for Voclosporin in SLE and LN, 2015-2025
  • Table 98: Other Promising Clinical-Stage Drugs in Development for SLE/LN, 2016
  • Table 99: Drugs in Development for SLE and LN, 2016
  • Table 100: Biosimilars Pipeline for RA, 2016
  • Table 101: Global Sales Forecasts ($m) for Biosimilars (Rituximab and Abatacept) in SLE and LN, 2015-2025
  • Table 102: Key Companies in the SLE and LN Market in the 7MM, 2016
  • Table 103: GSK's SLE and LN Portfolio Assessment, 2016
  • Table 104: Roche's SLE and LN Portfolio Assessment, 2016
  • Table 105: BMS' SLE and LN Portfolio Assessment, 2016
  • Table 106: AstraZeneca's SLE and LN Portfolio Assessment, 2016
  • Table 107: Merck KGaA's SLE and LN Portfolio Assessment, 2016
  • Table 108: Anthera's SLE and LN Portfolio Assessment, 2016
  • Table 109: Aurinia's SLE and LN Portfolio Assessment, 2016
  • Table 110: ImmuPharma's SLE and LN Portfolio Assessment, 2016
  • Table 111: Pfizer's SLE and LN Portfolio Assessment, 2016
  • Table 112: Global (7MM) Sales Forecasts ($m) for SLE and LN, 2015-2025
  • Table 113: SLE and LN Market - Global Drivers and Barriers, 2015?2025
  • Table 114: Sales Forecasts ($m) for SLE and LN in the US, 2015-2025
  • Table 115: Key Events Impacting Sales for SLE and LN in the US, 2015-2025
  • Table 116: SLE and LN Market - Drivers and Barriers in the US, 2015?2025
  • Table 117: Sales Forecasts ($m) for SLE and LN in the 5EU, 2015-2025
  • Table 118: Key Events Impacting Sales for SLE and LN in the 5EU, 2015-2025
  • Table 119: SLE and LN Market - Drivers and Barriers in the 5EU, 2015?2025
  • Table 120: Sales Forecasts ($m) for SLE and LN in Japan, 2015-2025
  • Table 121: Key Events Impacting Sales for SLE and LN in Japan, 2015-2025
  • Table 122: SLE and LN Market - Drivers and Barriers in Japan, 2015?2025
  • Table 123: Key Historical and Projected Launch Dates for SLE and LN
  • Table 124: Key Historical and Projected Patent Expiry Dates for SLE and LN
  • Table 125: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Overview of the Etiology and Pathogenesis of SLE
  • Figure 2: Integrated Hypothesis for the Pathogenesis of SLE
  • Figure 3: SLE Forecast Case Flow Map
  • Figure 4: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, 2015-2025
  • Figure 5: 7MM, Diagnosed Prevalent Cases of SLE, by Age, Both Sexes, N, 2015
  • Figure 6: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, 2015
  • Figure 7: 7MM, Age-Standardized Diagnosed Prevalence (Cases per 100,000 Population) of SLE, All Ages, by Sex, 2015
  • Figure 8: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, 2015
  • Figure 9: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, 2015?2025
  • Figure 10: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Classification, 2015
  • Figure 11: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Classification, 2015
  • Figure 12: Overview of the Treatment Management of SLE and LN
  • Figure 13: SLE and LN Therapeutics - Clinical Trials by Type of Therapy and Development Stage, December 2016
  • Figure 14: SLE and LN - Key Phase II?III Clinical Trials, 2016
  • Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2015-2025
  • Figure 16: Company Portfolio Gap Analysis in SLE and LN, 2015-2025
  • Figure 17: Average Annual Cost of Therapy (ACOT) for SLE and LN, 2016
  • Figure 18: Global (7MM) Sales for SLE and LN by Country/Region, 2015 and 2025
  • Figure 19: Global (7MM) Sales for SLE and LN by Region, 2015?2025
  • Figure 20: Global (7MM) Sales for SLE and LN by Drug, 2015 and 2025
  • Figure 21: Sales for SLE and LN by Drug Class in the US, 2015
  • Figure 22: Sales for SLE and LN by Drug Class in the 5EU, 2015 and 2025
  • Figure 23: Global Sales for SLE and LN by Country in the 5EU, 2015 and 2025
  • Figure 24: Global Sales for SLE and LN by Country in the 5EU, 2015?2025
  • Figure 25: Sales for SLE and LN by Drug Class in Japan, 2015 and 2025
Back to Top